Thrombocytopenia is most frequently encountered Hematological problem in hospitalized patients. The most common causes and differential diagnosis of In-patient and Outpatient presentations of Thrombocytopenia is discussed here. Useful for Internal Medicine Boards . Archer Internal Medicine Board review lectures will be released soon.
Aplastic anemia is one of the stem cell disorder which leads to pancytopenia in the peripheral blood and decrease production of all cell line in bone marrow. it require bone marrow transplantation to cure the patient.
THROMBOCYTOPENIA is decreased platelet count we call it thrombocytopenias. causes of this are called an infection, cancer condition, some type of the drugs like heparin, etc. signs and symptoms of the is bleeding tendency patiche, purpuraetc/ the management of this is plasma transfusion admin situation of some of the drug immunotherapy is helpful for this condition. surgery splenectomy.
Thrombocytopenia is generally defined as platelet count <150 × 109/L. It can occur due to several reasons, like decreased platelet production (e.g., inherited bone marrow failure syndromes, acquired aplastic anemia, leukemia), ineffective platelet production (myelodysplastic syndrome, megaloblastic anemia), increased destruction (ITP, HLH), increased consumption (DIC, TTP, HUS), sequestration (hypersplenism), or may be due to combination of multiple mechanisms described above.
During evaluating a case of thrombocytopenia, the first step is getting a detailed history and doing a proper clinical examination. Then the next step would be checking the other parameters of complete blood count (CBC), especially hemoglobin (Hb) and the total WBC count, complemented by a peripheral smear (PS) examination, which will clear many doubts and will help us pinpointing our diagnostic approach.
Many a times pseudo-thrombocytopenia is encountered in a PS due to platelet clumping by EDTA and can be rectified by collecting blood samples in a citrate or heparin vials or by doing a direct finger prick smear. Any accompanying cytopenia will expand the differential diagnosis and an isolated thrombocytopenia will further narrow it down. Presence of any additional abnormalities of red cells (megaloblasts) or white cells (presence of hyper-segmented neutrophils, atypical lymphoid/myeloid cells) could be present in megaloblastic anemia/MDS, leukemia respectively, while in the presence of fragmented red cells microangiopathic hemolytic anemia should always be ruled out by doing PT and aPTT (DIC, TTP, HUS). In case of isolated thrombocytopenia, the platelet morphology is also important. In many patients in India, especially in eastern region many people have large platelets with their normal platelet count around 100 × 109/L with normal platelet function (Harris platelet syndrome). However, presence of any abnormal platelet morphology along with a low platelet count may indicate a platelet function disorder (large platelets in Bernard Soulier syndrome/ Glanzmann thrombasthenia or small platelets in Wiskott-Aldrich syndrome), especially if encountered in early part of life during evaluation for bleeding symptoms. In case of isolated thrombocytopenia, presence of additional congenital anomalies may point out towards an inherited marrow failure syndrome, e.g. amegakayocytic thrombocytopenia. Exposure to certain drugs may result in isolated low platelet count, e.g., ceftriaxone, piperacillin, heparin. Presence of toxic changes in neutrophils may indicate sepsis related thrombocytopenia. By excluding all these, immune thrombocytopenia (ITP) to be thought as no specific tests or markers are available for this entity and its diagnosis is largely clinical. A further work up complemented by bone marrow examination and in few cases a platelet function test will definitely help in reaching the final diagnosis.
So, summarizing, in the evaluation of a case of thrombocytopenia, all the
Disseminated intravascular coagulation (DIC) is a syndrome in which either the extrinsic or intrinsic or both pathways are activated to produce multiple fibrin clots in small blood vessels.
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
What is Lymphoma?
Malignant lymphoma is a term given to tumors of the lymphoid system and specifically of lymphocytes and their precursor cells
i.e.
Cancer of the lymphatic system.
Many lymphomas are known to be due to specific genetic mutations.
When your blood has too few platelets, mild
to serious bleeding can occur. Bleeding can occur inside your body (internal
bleeding) or underneath your skin or from the surface of your skin (external
bleeding).
A normal platelet count in adults ranges
from 150,000 to 450,000 platelets per microliter of blood. A platelet count of
less than 150,000 platelets per microliter is lower than normal. If your blood
platelet count falls below normal, you have thrombocytopenia.
However, the risk for serious bleeding
doesn't occur until the count becomes very low—less than 10,000 or 20,000
platelets per microliter. Mild bleeding sometimes occurs when the count is less
than 50,000 platelets per microliter.
Many factors can cause a low platelet
count, such as:
-- The body's bone marrow doesn't make enough
platelets.
-- The bone marrow makes enough platelets, but
the body destroys them or uses them up.
-- The spleen holds on to too many platelets.
The spleen is an organ that normally stores about one-third of the body's
platelets. It also helps your body fight infection and remove unwanted cell
material.
-- A combination of the above factors.
-- How long thrombocytopenia lasts depends on
its cause. It can last from days to years.
The treatment for this condition also
depends on its cause and severity. Mild thrombocytopenia often doesn't require
treatment. If the condition causes or puts you at risk for serious bleeding,
you may need medicines or blood or
platelet transfusions. Rarely, the spleen may need to be removed.
Aplastic anemia is one of the stem cell disorder which leads to pancytopenia in the peripheral blood and decrease production of all cell line in bone marrow. it require bone marrow transplantation to cure the patient.
THROMBOCYTOPENIA is decreased platelet count we call it thrombocytopenias. causes of this are called an infection, cancer condition, some type of the drugs like heparin, etc. signs and symptoms of the is bleeding tendency patiche, purpuraetc/ the management of this is plasma transfusion admin situation of some of the drug immunotherapy is helpful for this condition. surgery splenectomy.
Thrombocytopenia is generally defined as platelet count <150 × 109/L. It can occur due to several reasons, like decreased platelet production (e.g., inherited bone marrow failure syndromes, acquired aplastic anemia, leukemia), ineffective platelet production (myelodysplastic syndrome, megaloblastic anemia), increased destruction (ITP, HLH), increased consumption (DIC, TTP, HUS), sequestration (hypersplenism), or may be due to combination of multiple mechanisms described above.
During evaluating a case of thrombocytopenia, the first step is getting a detailed history and doing a proper clinical examination. Then the next step would be checking the other parameters of complete blood count (CBC), especially hemoglobin (Hb) and the total WBC count, complemented by a peripheral smear (PS) examination, which will clear many doubts and will help us pinpointing our diagnostic approach.
Many a times pseudo-thrombocytopenia is encountered in a PS due to platelet clumping by EDTA and can be rectified by collecting blood samples in a citrate or heparin vials or by doing a direct finger prick smear. Any accompanying cytopenia will expand the differential diagnosis and an isolated thrombocytopenia will further narrow it down. Presence of any additional abnormalities of red cells (megaloblasts) or white cells (presence of hyper-segmented neutrophils, atypical lymphoid/myeloid cells) could be present in megaloblastic anemia/MDS, leukemia respectively, while in the presence of fragmented red cells microangiopathic hemolytic anemia should always be ruled out by doing PT and aPTT (DIC, TTP, HUS). In case of isolated thrombocytopenia, the platelet morphology is also important. In many patients in India, especially in eastern region many people have large platelets with their normal platelet count around 100 × 109/L with normal platelet function (Harris platelet syndrome). However, presence of any abnormal platelet morphology along with a low platelet count may indicate a platelet function disorder (large platelets in Bernard Soulier syndrome/ Glanzmann thrombasthenia or small platelets in Wiskott-Aldrich syndrome), especially if encountered in early part of life during evaluation for bleeding symptoms. In case of isolated thrombocytopenia, presence of additional congenital anomalies may point out towards an inherited marrow failure syndrome, e.g. amegakayocytic thrombocytopenia. Exposure to certain drugs may result in isolated low platelet count, e.g., ceftriaxone, piperacillin, heparin. Presence of toxic changes in neutrophils may indicate sepsis related thrombocytopenia. By excluding all these, immune thrombocytopenia (ITP) to be thought as no specific tests or markers are available for this entity and its diagnosis is largely clinical. A further work up complemented by bone marrow examination and in few cases a platelet function test will definitely help in reaching the final diagnosis.
So, summarizing, in the evaluation of a case of thrombocytopenia, all the
Disseminated intravascular coagulation (DIC) is a syndrome in which either the extrinsic or intrinsic or both pathways are activated to produce multiple fibrin clots in small blood vessels.
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
What is Lymphoma?
Malignant lymphoma is a term given to tumors of the lymphoid system and specifically of lymphocytes and their precursor cells
i.e.
Cancer of the lymphatic system.
Many lymphomas are known to be due to specific genetic mutations.
When your blood has too few platelets, mild
to serious bleeding can occur. Bleeding can occur inside your body (internal
bleeding) or underneath your skin or from the surface of your skin (external
bleeding).
A normal platelet count in adults ranges
from 150,000 to 450,000 platelets per microliter of blood. A platelet count of
less than 150,000 platelets per microliter is lower than normal. If your blood
platelet count falls below normal, you have thrombocytopenia.
However, the risk for serious bleeding
doesn't occur until the count becomes very low—less than 10,000 or 20,000
platelets per microliter. Mild bleeding sometimes occurs when the count is less
than 50,000 platelets per microliter.
Many factors can cause a low platelet
count, such as:
-- The body's bone marrow doesn't make enough
platelets.
-- The bone marrow makes enough platelets, but
the body destroys them or uses them up.
-- The spleen holds on to too many platelets.
The spleen is an organ that normally stores about one-third of the body's
platelets. It also helps your body fight infection and remove unwanted cell
material.
-- A combination of the above factors.
-- How long thrombocytopenia lasts depends on
its cause. It can last from days to years.
The treatment for this condition also
depends on its cause and severity. Mild thrombocytopenia often doesn't require
treatment. If the condition causes or puts you at risk for serious bleeding,
you may need medicines or blood or
platelet transfusions. Rarely, the spleen may need to be removed.
Hemostasis, Coagulation, Intrinsic, Extrinsic & common Pathways of Clotting, Common bleeding disorders & their investigations, BT, CT, PT, APTT, TT, Blood & its products, Blood transfusion & its complication.
Archer NCLEX Endocrine, DM, and Insulin - Live webinar.
Archer Review, a comprehensive reviewer for NCLEX-RN and NCLEX-PN exams, is focused on making quality and comprehensive test prep affordable to every nurse worldwide. Combine these crash courses along with Archer's highly popular NCLEX Qbanks with 2500 Qs that have consistently achieved a 97% pass rate.
This 3-hour Endocrinology, Diabetes, and insulin management crash course is one such webinar to shed light on one of the difficult and frequently tested topics on NCLEX. This is one of the several Archer content review crash courses to strengthen your concepts and face NCLEX more confidently. The idea of this webinar is to:
1. Go over all frequently tested NCLEX concepts in Endocrine disorders - Addison's, Cushing's, Thyroid, SIADH, Hyperparathyroidism, hypoglycemia, Diabetes, and Insulin management.
2. Endocrine diseases labs interpretation, Diabetes types/ concepts, insulin-related issues, diabetic diets, Client education, reduction of risk potential, and nursing interventions.
3. Provide you with challenge quizzes throughout the course after every class of disorders. You may actively participate by entering your answers or asking questions during Q and A sessions. Get your doubts clarified and understand concepts!
COST: just $10
Safety and infection control constitutes 12% of total items on NCLEX as per NCLEX-RN test plan. This webinar will explain all safety issues, isolation precautions frequently tested on NCLEX. Archer focus on SMART-PREP strategy by identifying th highly tested areas, preparing you thoroughly with content review webinars, and repeatedly challenging you with multiple questions from these areas in the Q-bank. Lowest focus is placed on areas that are tested less than 2% times but very high focus placed on areas tested more than 7% time in the test - this SMART-PREP strategy is the reason why Archer NCLEX achieves 99% PASS RATE even for the repeaters.
Slides from a must-know WEBINAR lecture for NCLEX -high-yield review of Dietary concepts and frequently tested nutrition topics with focus on client counseling, dietary advice in select in disease conditions, prioritization, and nursing interventions.
Syllabus for both ON-DEMAND and LIVE sessions - Syllabus - snapshot and detailed. Register at
ON-DEMAND access - 2months : -
https://ppv.audiovideoweb.com/ppvlnk/purchase/add/grp/160590567727448?id=06152009200616T
Live session: https://attendee.gotowebinar.com/register/8591903128354705678
A must-know for NCLEX -high-yield review of Cardiology concepts and frequently tested EKGs. Includes CAD, Sock, CHF, arrhythmias, asystole, hypertension, and many more. Cardiology and EKGs with focus on Prioritization, Nursing interventions, Client counseling, and all other high yield concepts to ace NCLEX system-wise!
Slides and handouts from Archer NCLEX Live and OnDemand webinars. These cover extensive NCLEX Highyield concepts topic-wise providing in-depth learning. Combine the content review with NCLEX
Archer NCLEX Webinars offer most comprehensive coverage of highyield concepts that are frequently tested on NCLEX. The goal is to explain you the fundamentals and reinforce your understanding with concurrent quizzing during webinars. Attendance is limited to focus on every single attendee. These slides are snapshots of what will be discussed during ARCHER NCLEX Pharmacology Webinar.
Archer Review is the most widely used Step 3 lecture and CCS course and has led to an extremely high pass rate even for repeaters. By focusing on what is tested frequently exam and mastering it from one single resource, reduce your prep-time by cutting back on referring to multiple sources! An Archer strategy that has worked time and again over a decade!
Infectious Diseases HighYield and Frequently tested concepts on USMLE Step 3. These slides are samples from Archer USMLE Step 3 Review Lectures. Couple it with Archer Step 3 Question bank and Step 3 CCS to easily pass your final part of USMLE licensing exams
Archer USMLE Step 3 CCS Workshop - Strategies and Slides. To be used with Archer CCS Video demonstrations/ CCS software practice demonstrations. Learn why CCS is crucial to pass Step 3 exam @ https://archerreview.com/ccs-cases/
Updated Archer USMLE Step 3 CCS Workshop sample slides reflecting new USMLE Step 3 CCS changes. Archer CCS Workshops will be organized every month and will demonstrate several highyield strategies to subscribers. Subscribers will also be involved in interactive practice of CCS cases during the live CCS webinar . Interact, participate, discuss and practice cases under supervision of expert teaching physicians without having to leave your home via. Archer Interactive live webinars. For those who can not attend live webinars and those that are more comfortable in reviewing CCS at their own convenience, Pay-per-view of our recorded CCS live webinars are available at https://archerreview.com/about-usmle-step3/
A comprehensive review of Cutaneous Lymphomas - both B-Cell and T-Cell with latest treatment strategies. Target audience are oncologists, dermatologists, oncology physicians, dermatology and oncology fellows
Target Audience: Oncology fellows and Oncologists
Carcinoma of unknown primary is a challenging scenario often encountered in Oncology practice. This slide presentation discusses favorable and unfavorable presentations of CUP and it's management
Target audience : Oncology fellows and Oncologists.
Four challenging cases of Bladder cancer and managing decisions including latest management principles are discussed here.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
The Art Pastor's Guide to Sabbath | Steve ThomasonSteve Thomason
What is the purpose of the Sabbath Law in the Torah. It is interesting to compare how the context of the law shifts from Exodus to Deuteronomy. Who gets to rest, and why?
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Thrombocytopenia
1. Hematology-High Yield Topics For Internal Medicine Boards and Hematology Boards Target Audience: Internal Medicine Residents, Family Medicine Residents, Hematology Fellows, Medical Students, IM Board Recertification exam aspirants Archer Internal Medicine Board Review www.CcsWorkshop.com
24. Systemic activation of coagulation Intravascular deposition of fibrin Depletion of platelets and coagulation factors Bleeding Thrombosis of small and midsize vessels with organ failure
25.
26.
27.
28. Lazarchick, J. ASH Image Bank 2001;2001:100174 Figure 1. Peripheral smear showing microangiopathic hemolytic features with numerous RBC fragments (helmet cells/schistocytes)
33. Moake J. N Engl J Med 2002;347:589-600 Proposed Relation among the Absence of ADAMTS 13 Activity in Vivo, Excessive Adhesion and Aggregation of Platelets, and Thrombotic Thrombocytopenic Purpura
34.
35.
36.
37.
38. 1. Pivetti S, et al. Br J Haematol. 1996;95:204-211. 2. Pawlotsky JM, et al. J Hepatol. 1995;23:635-639. 3. Sakuraya M, et al. Eur J. Haematol. 2002;68:49-53. 4. García-Suárez J, et al. Br J Haematol. 2000;110:98-103. 5. Rajan SK, et al. Br J Haematol. 2005;129:818-824. Study N Platelet Threshold, x 10 9 /L HCV Positive, n (%) Pivetti et al [1] 33 < 100 12 (36) Pawlotsky et al [2] 139 < 25 14 (10) Sakuraya et al [3] 79 < 10 11 (14) García-Suárez et al [4] 51 < 100 13 (23) Rajan et al [5] 250 < 100 76 (30)
52. HIT Temporal Variants Day 1 Day 4 Day 14 Day 30 Delayed-onset HIT (9–40 days) Rapid-onset HIT (hours–days) Typical HIT Mean Day 9 (5–14 days) Heparin (re) Exposure THROMBOCYTOPENIA (± THROMBOSIS)
53.
54.
55.
56.
57. Alternative Anticoagulants Drug Indications Argatroban FDA-approved for HIT (also for PCI) Lepirudin FDA-approved for HIT Bivalirudin (Angiomax) PCI (including HIT patients) Fondaparinux (Arixtra) FDA approved for DVT Prophylaxis in patients with Hip#, Hip or knee replacements. Also used in Rx of VTE. Not yet approved for HIT (Off-label use) Danaparoid Approved for HIT in Canada, Europe, Aust.
58.
59. Recommended Dosing Guidelines for Argatroban HIT Patients HIT Patients with Renal Impairment HIT Patients with Hepatic Impairment * Not to exceed a dose of 10 µg/kg/min or aPTT of 100 seconds † Due to approximate 4-fold decrease in Argatroban clearance relative to those with normal hepatic function Initiate at 2 µg/kg/min Titrate until steady-state aPTT is 1.5–3.0 times baseline value* No dosage adjustment required Initiate at 0.5 µg/kg/min † Titrate until steady-state aPTT is 1.5–3.0 times baseline value*
60.
61. Guidelines for Conversion to Oral Anticoagulant Therapy If INR is below the therapeutic range for warfarin alone, resume Argatroban therapy If INR is >4.0, stop Argatroban infusion Initiate warfarin therapy using the expected daily dose of warfarin while maintaining Argatroban infusion. * A loading dose of warfarin should not be used If INR is within therapeutic range on warfarin alone, continue warfarin monotherapy If INR is 4.0, continue concomitant therapy Repeat INR 4-6 hours later Measure INR daily * For Argatroban infusion at 2 µg/kg/min, the INR on monotherapy may be estimated from the INR on cotherapy. If the dose of Argatroban >2 g/kg/min, temporarily reduce to a dose of 2 g/kg/min 4-6 hours prior to measuring the INR.
Schematic representation of the origin and development of megakaryocytes : - The pluripotential stem cell produces a progenitor cell committed to megakaryocyte differentiation (Meg-CFC) which undergoes mitosis. The Meg-CFC eventually stops mitosis and enters endomitosis during which neither cytoplasm nor nucleus divides but DNA replication proceeds and gives rise to polyploid immature precursor cells. Upon completion of endomitosis, the immature progenitor cells become large, morphologically identifiable mature megakaryocytes MEGAKARYOCYTE now sheds the platelets. ( non nuclear particles)
Having said that, it should be remembered that a recent fall in platelet count by 50% even though with in normal range may precede severe clinical issues and must be actively monitored. One good example is HIT.
Although pseudothrombocytopenia has no pathologic significance and will not increase thrombotic or hemorrhagic risk, failure to recognize it may potentially place a patient in jeopardy for inappropriate discontinuation of the needed drug, delay of therapies involving invasive procedures, or initiation of unnecessary therapies, such as platelet transfusion or use of steroids. 1 , 10 , 12 In the case reported here, olanzapine would not have been discontinued if an early distinction between pseudothrombocytopenia and drug-induced immune thrombocytopenia had been made.
After abciximab bolus, abciximab PTCP occurs as soon as 2hrs after the bolus and starts normalizing from 3days after the dose. ( Note that even in EDTA blood pseudo-thrombocytopenia recovers 3 days after the bolus as abciximab effect on GP Iib/IIIA wears off). Peripheral smear shows clumps in EDTA blood. Note that in citrate blood, platelet count remains normal in Abciximab related PTCP ( in contrast to true abciximab TP, where platelet clumps are not seen in EDTA smear and platelet counts are low in citrate blood smear as well)
WHEN REQUIRED PLATELETS COME OUT OF THE SPLEEN
PNH can lead to drop in all cell lines if the mutation occurs in stem cells instead of red cell precursor alone. Cells deficient in CD55 and CD59 which protects them from complement mediated destruction
DIC can be better called as consumption coagulopathy – there is activation of entire coagulation cascade with deposition of fibrin thrombi in the vessels that can lead to thromboses of small and mid size vessels multi organ failure and also, MAHA. Consumption of clotting factors will cause prolonged PT, PTT and reduced fibrinogen. Consumption of plats cause thrombocytopenia that can lead to bleeding complications in some cases.
Most cases of TTP occur because of congenital or acquired deficiency of ADAMT13 or secondary to acquired inhibitor to ADAMTS13 – an enzyme that normally cleaves large VWF multimers
Figure 2. Proposed Relation among the Absence of ADAMTS 13 Activity in Vivo, Excessive Adhesion and Aggregation of Platelets, and Thrombotic Thrombocytopenic Purpura. In Panel A, in normal subjects, ADAMTS 13 (von Willebrand factor-cleaving metalloprotease) molecules attach to binding sites on endothelial-cell surfaces and cleave unusually large multimers of von Willebrand factor as they are secreted by stimulated endothelial cells. The smaller von Willebrand factor forms that circulate after cleavage do not induce the adhesion and aggregation of platelets during normal blood flow. ADAMTS 13 may use one of its thrombospondin-1-like domains or its arginine-glycine-aspartate (RGD) sequence to attach to the surface of endothelial cells. In Panel B, absent or severely reduced activity of ADAMTS 13 in patients with thrombotic thrombocytopenic purpura prevents timely cleavage of unusually large multimers of von Willebrand factor as they are secreted by endothelial cells. The uncleaved multimers induce the adhesion and aggregation of platelets in flowing blood. A congenital deficiency of ADAMTS 13 activity, or an acquired defect of ADAMTS 13 (such as that caused by autoantibodies or by a change in the production or survival of the protein) can lead to thrombotic thrombocytopenic purpura. Interference with the attachment of ADAMTS 13 to endothelial cells in vivo (for example, as a result of ADAMTS 13-receptor blockade by other types of autoantibodies) may also cause thrombotic thrombocytopenic purpura in patients with normal ADAMTS 13 activity in plasma.
Steroids must be used as adjuncts in patients whose platelet count does not increase within several days of treatment with plasma exchange or in those who TP recurs when plasmapheresis is being tapered or discontinued.
Further evidence suggesting that splenomegaly and portal hypertension are not the only factors to explain thrombocytopenia in chronic liver disease is the finding that thrombocytopenia has been shown to endure after surgical portal decompression with transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.
Several studies have found increased prevalence of HCV with out overt liver disease in chronic ITP patients between 10 to 30%. Hence, even in the absence of hepatitis or overt liver disease, HCV serology should always be obtained in evaluating the patients with ITP before labelling them as idiopathic ITP . This could turn out to be HCV-related ITP.
Low baseline platelets < 70k lead to postponement of therapy. Even if the platelets were higher prior to initiation of therapy, they may fall during therapy requiring dose adjustments and hence, less optimal treatment Postponement of treatment due to thrombocytopenia can result in diminished sustained virologic response because of the potential for further progression of liver disease in the absence of treatment. Dose modifications may lower the chances of sustained virological response
Platelet transfusions are not used just because treatment can be started or treatment can be continued with interruption. Such practice does not help because transfused platelets will not produce a proper response required and also, their life span is not enough to continue prolonged HCV therapy. Multiple platelet transfusions can cause platelet refractoriness ( alloimmunization) and also, other transfusion related complications.
The study enrolled 74 patients with evidence of liver damage, which was characterized as a liver biopsy indicating chronic hepatitis and cirrhosis or radiographic evidence of cirrhosis or nonbleeding gastroesophageal varices and compensated liver disease (Child-Pugh A). Inclusion criteria included presence of thrombocytopenia at platelet counts of 20,000-70,000 cells/µL, whereas patients were excluded for a history of thrombosis, HIV infection, or active hepatitis B virus infection. Patients received 30, 50, or 75 mg/day eltrombopag or placebo daily for 4 weeks. After 4 weeks, patients were evaluated before initiation of the antiviral treatment phase of the trial. Criteria for initiation of antiviral therapy with peginterferon and ribavirin included platelet counts of > 70,000 cells/µL for patients receiving peginterferon alfa-2a or > 100,000 cells/µL for individuals receiving peginterferon alfa-2b. Patients who met these criteria received antiviral therapy plus eltrombopag for an additional 12 weeks. Results from the initial 4 weeks of this study are presented in the Table. The initial eltrombopag pretreatment resulted in significant increases in platelet counts at Week 4 in all treatment groups. The number of patients able to initiate antiviral treatment ranged from 71% to 91% with eltrombopag vs 22% in the control arm. In total, 65% of patients in the 75-mg dose group, 53% of patients in the 50-mg dosing group, and 36% of patients in the 30-mg dosing group were able to complete the 12-week antiviral therapy phase compared with 6% of placebo-treated patients ( P < .001, P not provided, and P = .003, respectively).
Heparin-Induced Thrombocytopenia (HIT): An Overview Key Point: Broad overview of what the presentation will discuss in detail. The anticoagulant heparin is used in more than 12 million patients per year 1 for treating and preventing thromboembolic disorders in medical and surgical patients. 2 Its importance as an anticoagulant has been well established by its effectiveness, rapid onset of action, ease of laboratory monitoring, and cost. Heparin can cause 2 forms of thrombocytopenia. This slide kit is primarily concerned with immune-mediated thrombocytopenia, or HIT, which occurs in up to 1% to 3% of patients receiving unfractionated heparin and in up to 2% of patients undergoing orthopedic surgery receiving low molecular weight heparin (LMWH). 2 HIT is a serious condition with about 50% of patients at risk of life- or limb-threatening thromboses if they remain untreated. 3 All forms of heparin should be discontinued in the presence of HIT. 4,5 An alternate anticoagulant should be strongly considered to treat HIT as well as the underlying condition. The Food and Drug Administration (FDA) has approved 2 anticoagulants for use in patients with HIT, lepirudin and argatroban. 1. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs . 1995;13(4):112-116. 2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335. 3. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507. 4. Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin- induced thrombocytopenia. Pharmacotherapy. 1999;19(2):181-195. 5. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol. 1995;89(3):431-439.
HIT is an immune disease resulting in an extremely pro thrombotic state. HIT occurs due to presence of IgG antibodies that recognize heparin-PF4 complexes. Initially, Platelet activation leads to release of platelet factor 4 (PF4) and microparticles. The heparin that is administered forms complexes with PF4 the IgG antibodies that are already present ( from prior sensitization or from de novo formation during this exposure) now react with PF4-heparin complexes to form circulating immune complexes (PF4-heparin-IgG) which then bind to Fc receptors on the platelets thereby, activating the platelets further leading to further release of microparticles and more PF4 and activation of the coagulation pathways through platelet-derived microparticles thus setting off prothrombotic state
HIT is classified as two types HIT Type 1 which is non immune mild TP ( >100k) associated with heparin that occurs with in first five days of heparin. This is not associated with thrombosis or antibody formation and platelet count recovers despite continuing Heparin. This is probably secondary to tiny platelet aggregates.
30 – 50% of patients presenting with HIT experience a thrombotic event within 30 days. Morbidity and mortality are significant in patients with HIT despite discontinuation of heparin therapy. Death can occur in 30% cases if untreated.
Venous complications were observed more frequently than arterial events in a ratio of approximately 4:1. 3 The early symptoms of venous thrombosis may not be obvious. The most common venous thrombotic complication was deep vein thrombosis, which was responsible for more than 60% of thrombotic events in one study, followed by pulmonary embolism, which was responsible for 25% of all events. 3, 11 Arterial events are generally evidenced by overt clinical symptoms and may be life or limb threatening. In a single patient, significant clot extensions or multiple sites of thrombosis may occur. 5, 15
HIT can be of 3 types based on the time of onset. Early onset HIT can occur with in 5 days of heparin re-exposure and is due to pre-existing circulating anti-PF4 antibodies due to prior recent exposure to heparin in the past 3 months ( the antibodies can exist up to 90 days after initial exposure to heparin). Typical HIT occurs between 5 to 14 days after exposure to heparin. Some patients may have delayed onset HIT which can start as late as 9 days after exposure to heparin and may occur until 40 days after exposure. HIT can occur up until 30 days even after stopping heparin due to circulating antibodies.
HIT is a clinical diagnosis. Pre-test probabilty must be estimated by using 4T score. Most laboratory tests have long turnaround time and hence, therapy must not be delayed if pretest is high or intermediate.
While these tests are helpful in confirming HIT, the diagnosis remains a clinical one since there is wide variability of, access to, and turnaround time for these assays. There is wide variability in sensitivity and specificity. If SRA is only 95% sensitive, a negative SRA will nor rule out HIT if clinical
Direct Thrombin inhibitors : argatroban, lepirudin, bivalirudin. Fondaparinux : Is a INDIRECT inhibitor of Factor Xa. ( does not belong to class of direct thrombin inhibitors) The combination of once-daily subcutaneous administration, predictability of response, and minimal adverse effects makes fondaparinux an appealing alternative anticoagulant for patients with HIT. Although clinical experience with this agent in the setting of HIT is limited, the successful use of fondaparinux in patients with HIT has been reported. To date, one multicenter, blinded, comparative, in vitro study has demon-strated a lack of cross-reactivity between fondaparinux and HIT antibodies. At this time, use of fondaparinux in the setting of HIT is not recommended by the American College of Chest Physicians. Rather, the direct thrombin inhibitors lepirudin and argatroban are recommended as first-line agents. Nevertheless, limited clinical experience suggests that fondaparinux may be an alternative for anticoagulation in patients with HIT. Large, in vivo comparison trials must be performed before fondaparinux can become a standard treatment option in the setting of HIT
Dosing for Argatroban is relatively straightforward. 17 The initial dose of Argatroban is 2 g/kg/min; the mean dose during clinical studies was 2 g/kg/min, indicating dose titration for many patients may not be necessary to achieve adequate anticoagulation. No dosage adjustment is necessary in patients with renal impairment. For patients with hepatic impairment, the dose should be reduced to 0.5 g/kg/min.
If argatroban infusion rate is >2mcg/kg/min reduce dose to <2mcg/kg/min first and then, measure inr after 4 hours – now, if INR > 4, can stop argatroban
Why less than 100k : A prospective cohort of healthy subjects with platelet counts between 100 and 150 x 10 9 /L had a 10-yr probability of developing persistent platelets counts < 100 x 10 9 /L of only 6.9% . Defined in 3 stages: newly diagnosed (< 3 mos), persistent (3-12 mos), and chronic (> 12 mos) [1] Why : Defining patients as acute vs chronic is a retrospective determination; the new stage definitions will allow for better selection of patients for clinical trials
In the summer of 1950, two hematology fellows working at the Barnes Hospital in St. Louis — William J. Harrington and James W. Hollingsworth — hatched a plan to test their idea that the cause of the idiopathic thrombocytopenic purpura (ITP) in a woman under their care was a factor in the blood that destroyed platelets. They decided that of the two fellows, the one whose blood type matched the patient's would receive 500 ml of her blood. In a flip of the genetic coin, Harrington matched. Within a few hours after receiving the woman's blood, Harrington's platelet count dropped.
ALPS, autoimmune lymphoproliferative syndrome; APS, antiphospholipid syndrome; CLL, chronic lymphocytic leukemia; CVID, common variable immune deficiency; Hep C, hepatitis C virus; H. pylori, Helicobacter pylori; ITP, immune thrombocytopenia; SLE, systemic lupus erythematosus. Immune thrombocytopenia can occur in conjunction with a number of other disorders. In this figure taken from a paper by Cines and colleagues published in Blood in 2009, primary ITP encompasses about 80% of all ITP; the other disorders listed in the breakout are all causes of secondary ITP. These include systemic lupus erythematosus (5%), antiphospholipid syndrome (2%), common variable immunodeficiency, and chronic lymphocytic leukemia, for example. These are all disorders that are generally immune related and can be associated with an ITP-like syndrome or secondary ITP.
Some infectious causes of ITP are well recognized such as HIV related ITP, HCV and H.pylori. Rx for HIV-TP is HAART and other modalities of ITP rx. Rx HCV-TP discussed earlier. If H.Pylori antigen detected, may try h.pylori eradication therapy first before using more toxic therapies. CAG A strains of H.Pylori are implicated in ITP.
B- and T-cell responses in ITP — B cell autoimmune IgG responses in ITP appear to be driven by CD4+ helper T cells reacting to platelet membrane glycoprotein epitopes - possibly involving CD40:CD40L co-stimulation processes , with splenic macrophages as the major antigen-presenting cells.
In a bleeding patient with ITP, give plt transfusion after IVIG . Steroid added as well. When urgent increase needed always IVIG vs. Anti D